Why is Pralsetinib not covered by medical insurance?

Pralsetinib (Pralsetinib) is mainly used to treat a specific type of cancer, namely RET fusion-positive tumors. Mutations in the RET gene are one of the common mutations in many cancers, including thyroid cancer and non-small cell lung cancer. Platinib blocks the growth and spread of cancer cells by inhibiting the activation of RET protein. Platinib can slow the progression of RET fusion-positive tumors and cause tumors to shrink or disappear in some patients. Platinib may improve survival and quality of life in patients with unresectable or metastatic RET fusion-positive tumors. Everyone's condition is different and their response to platinib will be different. Before using platinib, you should consult your doctor to determine its appropriateness for your individual condition and to fully understand the possible side effects and precautions.

It is understood that the original drug Platinib has been marketed in China, but it has not yet entered the scope of medical insurance through the relevant regulations of the Medical Insurance Bureau. Patients in need can currently only purchase it at their own expense. The price of each box of 100mg*120 tablets may be around RMB 60,000, which is expensive. For specific medical insurance information, please consult the local Medical Insurance Bureau and other places. The price of the European version of 100mg*60 capsules sold overseas may be around 40,000 yuan per box, and the price of the American version may be around 150,000 yuan per box (prices may fluctuate due to exchange rates). The ingredients of domestic and foreign original drugs are basically the same. There is currently no generic version of Platinib available on the market. Please consult your medical consultant for specific prices and drug details.